Please login to the form below

FDA approves 14 generic copies of GSK's Coreg

The FDA allows 14 generic manufacturers to sell first generic versions of GlaxoSmithKline's blood pressure drug Coreg in the US

The FDA has given 14 generic manufacturers permission to sell the first generic versions of GlaxoSmithKline's (GSK) blood pressure drug Coreg (carvedilol) on the US market.

The agency stated on 5 September 2007 that the companies, which included Caraco Pharmaceutical, Mylan, Ranbaxy and Watson, could sell generic versions of Coreg in strengths of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.

Coregis is approved in the US to treat high blood pressure, mild-to-severe chronic heart failure and left ventricular dysfunction following a heart attack.

GSK sells a newer, daily reformulation of the drug called Coreg CR, which is patent protected until 2023, according to the UK-based firm.

30th September 2008

PME Digital Edition

Featured jobs

Account Manager / Account Director: Competative

Account Manager: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Experienced Medical Writers: Competitive Salary and Benefits

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Account Executive/ Senior Account Executive: competitive Salary Offfered

Medical Writer: Salary TBC

Account Director: Competitive Salary Offered

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Associate Director: £75, 000-90, 000

Account Manager- Healthcare Advertising: Negotiable

Account Director – Healthcare Marketing – Berks: Salary TBC

Associate Medical Director: Excellent PTO, bonus and 401k package

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Editorial Manager - MedComms: DOE

Business Director: Competitive Salary Offered

Senior Account Manager: Competitive Salary Offered

Senior Account Executive with progression to Account Manager, Me...: Excellent package

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Systematic Reviewer - Oxford: Negotiable

Medical (Scientific) Director: £120, 000 benefits

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Editorial Assistant – Greater Manchester: DOE

Is China ready for a pharmaceutical gold rush?: Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...